Avacta Group (AVCT) RNS Announcements

Add to Alert list
Date Time Source Announcement
10 Oct 2024 07:00 AM
RNS
Avacta Unveils Pipeline Expansion at EORTC 2024
10 Oct 2024 07:00 AM
GNW
Avacta to Unveil Pipeline Expansion and Novel...
30 Sep 2024 07:00 AM
RNS
Interim Results
16 Sep 2024 07:00 AM
RNS
Avacta Reported Updated Phase 1 Data of AVA6000
14 Sep 2024 08:00 AM
GNW
Avacta Reports Updated Phase 1 Clinical Data ...
12 Sep 2024 07:00 AM
RNS
Notice of Results
09 Sep 2024 07:00 AM
RNS
Avacta to present clinical data at ESMO Congress
08 Sep 2024 11:05 PM
GNW
Avacta to present updated clinical data on AV...
02 Sep 2024 03:53 PM
RNS
Director/PDMR Shareholdings and TVR
18 Jul 2024 07:00 AM
RNS
Convertible Bond Payment
26 Jun 2024 02:46 PM
RNS
Result of AGM
26 Jun 2024 07:00 AM
RNS
AGM Business Update
20 Jun 2024 07:00 AM
RNS
Shaun Chilton appointed Non-Executive Chairman
11 Jun 2024 07:00 AM
RNS
Appointment of Nominated Adviser and Sole Broker
31 May 2024 07:00 AM
RNS
Posting of Annual Report and Notice of AGM
23 May 2024 07:00 AM
RNS
Successful Completion of First Cohort
30 Apr 2024 07:01 AM
RNS
Full Year Results
30 Apr 2024 07:00 AM
RNS
Board Change
26 Apr 2024 09:51 AM
RNS
Block listing Interim Return REPLACEMENT
26 Apr 2024 07:00 AM
RNS
Block Listing Six Monthly Return
23 Apr 2024 09:43 AM
RNS
Block Listing Application to AIM
23 Apr 2024 07:00 AM
RNS
Notice of Results
22 Apr 2024 12:14 PM
RNS
Issue of Equity and Total Voting Rights
22 Apr 2024 12:14 PM
RNS
Issue of Equity and Total Voting Rights
09 Apr 2024 05:00 PM
RNS
Avacta Reports Data at the AACR Annual Meeting
08 Apr 2024 07:00 AM
RNS
AVA6000 Abstract Release by AACR
05 Apr 2024 09:30 PM
GNW
Avacta Group - AVA6000 Abstract Release by AA...
28 Mar 2024 04:00 PM
RNS
Investor Webinar
21 Mar 2024 07:00 AM
RNS
Update on AVA6000 Phase 1a Clinical Trial Progress
18 Mar 2024 01:26 PM
RNS
Result of General Meeting
06 Mar 2024 07:00 AM
RNS
Avacta Announces AVA6000 Poster at AACR
05 Mar 2024 07:00 AM
RNS
Result of REX Retail Offer
29 Feb 2024 07:00 AM
RNS
Result of Placing
28 Feb 2024 04:42 PM
RNS
Proposed REX Retail Offer
28 Feb 2024 04:41 PM
RNS
Proposed Fundraise to progress Therapeutics
16 Feb 2024 07:00 AM
RNS
Share Incentive Plan/Issue of Equity
22 Jan 2024 10:51 AM
RNS
Issue of Equity and Total Voting Rights
19 Jan 2024 07:00 AM
RNS
Appointment of Christina Coughlin
19 Dec 2023 07:00 AM
RNS
Appointment of Chief Business Officer
13 Dec 2023 07:00 AM
RNS
ALS-6000-101 Phase 1a Study Data
04 Dec 2023 07:00 AM
RNS
Shareholder update to review AVA6000 Phase 1a data
27 Oct 2023 07:00 AM
RNS
Block Listing Six Monthly Return
23 Oct 2023 01:30 PM
RNS
Issue of Equity and Total Voting Rights
18 Oct 2023 01:00 PM
RNS
Block Listing Application to AIM
05 Oct 2023 07:00 AM
RNS
Avacta to present at AACR-NCI-EORTC conference
29 Sep 2023 01:30 PM
RNS
Director/PDMR Shareholding
28 Sep 2023 07:00 AM
RNS
Interim Results for the Period Ending 30 June 2023
20 Sep 2023 02:00 PM
RNS
Issue of Equity and Total Voting Rights
20 Sep 2023 07:01 AM
RNS
Peel Hunt Appointed as Joint Broker
20 Sep 2023 07:00 AM
RNS
Appointment Dr.Christina Coughlin as a consultant

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics.

It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Avacta Group share price launched at 5,448p in 2003. 

UK 100

Latest directors dealings